Abstract
Donor pancreatic lymph node cells (PLNC) protect islet transplants in Non-obese diabetic (NOD) mice. We hypothesized that induced FoxP3 + regulatory T cells (Tregs) were required for long-term islet engraftment. NOD or NOD.NON mice were treated with ALS (antilymphocyte serum) and transplanted with NOR islets +/-PLNC (5 × 10 7). In vivo proliferation and expansion of FoxP3 + Tregs was monitored in spleen and PLN from ALS- and ALS/PLNC-treated recipient mice. Anti-CD25 depletion was used to determine the necessity of Tregs for tolerance. FoxP3 + numbers significantly increased in ALS/PLNC-treated recipients compared to ALS-treated mice. In ALS/PLNC-treated mice, recipient-derived Tregs localized to the transplanted islets, and this was associated with intact, insulin-producing β cells. Proliferation and expansion of FoxP3 + Tregs was markedly increased in PLNC-treated mice with accepted islet grafts, but not in diabetic mice not receiving PLNC. Deletion of Tregs with anti-CD25 antibodies prevented islet graft tolerance and resulted in rejection. Adoptive transfer of Tregs to secondary NOD.scid recipients inhibited autoimmunity by cotransferred NOD effector T cells. Treg expansion induced by ALS/PLNC-treatment promoted long term islet graft survival. Strategies leading to Treg proliferation and localization to the transplant site represent a therapeutic approach to controlling recurrent autoimmunity. This study demonstrates the critical role of recipient regulatory T cell proliferation and expansion in the protection of islet transplants from recurrent autoimmunity.
Original language | English |
---|---|
Pages (from-to) | 1124-1132 |
Number of pages | 9 |
Journal | American Journal of Transplantation |
Volume | 12 |
Issue number | 5 |
DOIs | |
State | Published - May 2012 |
Externally published | Yes |
Keywords
- Antilymphocyte antibodies
- NOD mice
- autoimmunity
- diabetes mellitus
- donor T cell
- islet cells
- regulatory cells